BioNeutral (BONU) Inactive 10-Q14 Mar 142014 Q1 Quarterly reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
Document and Entity Information	Jan. 31, 2014	Feb. 26, 2014
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'BioNeutral Group, Inc	'
Entity Central Index Key	'0001427030	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--10-31	'
Document Type	'10-Q	'
Document Period End Date	31-Jan-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q1	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	1,037,920,656

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Jan. 31, 2014	Oct. 31, 2013
Current Assets	'	'
Cash	$1,244	$702
Accounts Receivable - Net	3,878	9,911
Inventory	16,520	14,493
Total Current Assets	21,642	25,106
Property and Equipment - Net	304	357
Intellectual Property - Net	9,072,317	9,249,498
Other Assets	2,500	2,500
TOTAL ASSETS	9,096,763	9,277,461
Current Liabilities	'	'
Accounts Payable and Accrued Expense	1,092,912	1,087,876
Current Portion of Convertible Notes Payable, net of discount of $86,743 and $91,167 respectively	267,456	267,716
Current Portion of Convertible Loans from Stockholders	77,646	75,000
Accrued Compensation	1,355,892	978,851
Related Party Payables	58,026	57,508
Derivative Liability	156,913	129,425
Current Liabilities	3,008,845	2,596,376
Long Term Liabilities	'	'
Convertible Loans From Stockholders - net of current portion	1,533,272	1,462,291
Total Long Term Liabilities	1,533,272	1,462,291
TOTAL LIABILITIES	4,542,117	4,058,667
Commitments and Contingencies	'	'
BioNeutral Group, Inc. Stockholders' Equity	'	'
Common Stock, $.00001 Par Value; 4,000,000,000 shares authorized, 798,088,296 and 252,034,393 issued and outstanding at January 31, 2014 and October 31, 2013, respectively.	7,980	2,520
Additional Paid-in Capital	63,553,691	63,402,660
Due from Vinfluence	-136,848	-136,848
Accumulated Deficit	-58,640,453	-57,889,075
Total BioNeutral Group, Inc. Stockholders' Equity	4,784,608	5,379,495
Non controlling Interest	-230,021	-160,760
Preferred Stock, $.001 par value; 5,000,000 shares authorized, with 800,000 designated as follows Convertible Preferred Stock, Series A, $.001 par value; 800,000 shares authorized, 59,484 shares issued and outstanding at January 31, 2014 and October 31, 2013, respectively. Liquidation Preference $1,072,361 at January 31, 2014 and October 31, 2013, respectively	59	59
Total Non controlling Interest	-229,962	-160,701
Total Equity	4,554,646	5,218,794
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	9,096,763	9,277,461
Convertible Preferred Stock Series B	'	'
BioNeutral Group, Inc. Stockholders' Equity	'	'
Preferred Stock, $.001 par value	54	54
Convertible Preferred Stock Series C	'	'
BioNeutral Group, Inc. Stockholders' Equity	'	'
Preferred Stock, $.001 par value	56	56
Convertible Preferred Stock Series D	'	'
BioNeutral Group, Inc. Stockholders' Equity	'	'
Preferred Stock, $.001 par value	128	128
Convertible Preferred Stock Series E	'	'
BioNeutral Group, Inc. Stockholders' Equity	'	'
Preferred Stock, $.001 par value	'	'
Convertible Preferred Stock, Series F	'	'
BioNeutral Group, Inc. Stockholders' Equity	'	'
Preferred Stock, $.001 par value	'	'

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Jan. 31, 2014	Oct. 31, 2013
Net of discount on convertible notes payable current	$86,743	$91,167
Preferred stock shares designated	684,600	684,600
Preferred Stock, par value (in dollars per shares)	$0.00	$0.00
Preferred Stock, shares authorized	10,000,000	10,000,000
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	4,000,000,000	4,000,000,000
Common stock, shares issued	798,088,296	252,034,393
Common stock, shares outstanding	798,088,296	252,034,393
Temporary equity shares designated	800,000	800,000
Series A Preferred stock, par value	$0.00	$0.00
Series A Preferred stock, shares authorized	5,000,000	5,000,000
Convertible Preferred Stock Series B	'	'
Preferred Stock, par value (in dollars per shares)	$0.00	$0.00
Preferred Stock, shares authorized	213,500	213,500
Preferred Stock, Shares Issued	53,491	53,491
Preferred Stock, Shares Outstanding	53,491	53,491
Preference Liquation, Value	534,910	534,910
Convertible Preferred Stock Series C	'	'
Preferred Stock, par value (in dollars per shares)	$0.00	$0.00
Preferred Stock, shares authorized	100,000	100,000
Preferred Stock, Shares Issued	56,081	56,081
Preferred Stock, Shares Outstanding	56,081	56,081
Preference Liquation, Value	560,810	560,810
Convertible Preferred Stock Series D	'	'
Preferred Stock, par value (in dollars per shares)	$0.00	$0.00
Preferred Stock, shares authorized	231,100	231,100
Preferred Stock, Shares Issued	128,251	'
Preferred Stock, Shares Outstanding	128,251	'
Preference Liquation, Value	1,282,510	'
Convertible Preferred Stock Series E	'	'
Preferred Stock, par value (in dollars per shares)	$0.00	$0.00
Preferred Stock, shares authorized	140,000	140,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Preference Liquation, Value	0	0
Convertible Preferred Stock, Series A	'	'
Preferred Stock, par value (in dollars per shares)	$0.00	$0.00
Preferred Stock, shares authorized	800,000	800,000
Preferred Stock, Shares Issued	59,484	'
Preferred Stock, Shares Outstanding	59,484	'
Preference Liquation, Value	$1,072,361	$1,072,361
Convertible Preferred Stock, Series F	'	'
Preferred Stock, par value (in dollars per shares)	$0.00	$0.00
Preferred Stock, shares authorized	51	51
Preferred Stock, Shares Issued	51	0
Preferred Stock, Shares Outstanding	51	0

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended
	Jan. 31, 2014	Jan. 31, 2013
Statements Of Operations [Abstract]	'	'
Revenues	$7,004	$555
Cost of Revenues	1,931	203
Gross Profit	5,073	352
Operating Expenses	'	'
Depreciation and Amortization	177,234	177,234
Salaries and Wages	129,131	208,404
Consulting Expense	117,300	10,150
Legal and Accounting Expenses	107,643	146,607
Other Selling, General and Administrative Expenses	168,026	138,831
Total Operating Expenses	699,334	681,226
Loss from Operations	-694,261	-680,874
Other Income (Expense)	'	'
Interest Expense	-94,467	-32,739
Amortization of Debt Discount	-40,424	-109,642
Change in Fair Value of Derivative Liability	8,512	61,875
Total Other Income (Expense)	-126,379	-80,506
Loss Before Provision for Income Taxes	-820,640	-761,380
Provision for Income Taxes	'	'
Net Loss	-820,640	-761,380
Net Loss Attributable to Non-controlling Interest	69,262	64,260
Net Loss Attributable to BioNeutral Group, Inc.	($751,378)	($697,120)
Net Loss Per Common Share - Basic and Diluted	($0.01)	($0.01)
Weighted Average Number of Common Shares outstanding Basic and Diluted	317,171,673	125,491,943

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	3 Months Ended
	Jan. 31, 2014	Jan. 31, 2013
CASH FLOWS FROM OPERATING ACTIVITIES	'	'
Net Loss	($820,640)	($761,380)
Adjustments to Reconcile Net Loss To Net Cash Used in Operating Activities	'	'
Stock Based Compensation	-72,264	'
Depreciation and Amortization	177,234	177,234
Issuance of Stock related to professional services	10,000	108,805
Interest added to promissory notes	57,499	29,408
Non-Cash Interest	'	109,642
Change in Fair Value of Derivative Liability	-8,512	-61,875
Amortization of Debt Discount	40,424	109,642
Changes in Operating Assets and Liabilities	'	'
Accounts Receivable	6,033	'
Inventory	-2,027	203
Prepaid Expenses - Employee Advances	'	-52,292
Other Assets	'	10,015
Accounts Payable and Accrued Expenses	413,277	131,165
Related Party Payables	518	1,036
NET CASH USED IN OPERATING ACTIVITIES	-198,458	-308,039
CASH FLOWS FROM FINANCING ACTIVITIES	'	'
Proceeds from Exchangeable Promissory Notes	199,000	308,000
NET CASH PROVIDED BY FINANCING ACTIVITIES	199,000	308,000
NET INCREASE (DECREASE) IN CASH	542	-39
CASH, BEGINNING OF PERIOD	702	676
CASH, END OF PERIOD	1,244	637
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION	'	'
Cash paid for Interest	'	'
Cash paid for Income Taxes	'	'
SUPPLEMENTAL DISCLOSURE OF NON-CASH INFORMATION	'	'
Non-cash settlements of Accounts Payable and Accrued Expenses	-31,200	'
Non-cash conversion of promissory notes to common stock	-187,556	'
Aggregate value of derivative liability	($36,000)	'

Nature_of_Business_Organizatio

Nature of Business & Organization	3 Months Ended
Nature of Business & Organization	Jan. 31, 2014
Nature Of Business and Organization [Abstract]	'
Nature of Business and Organization	'
	Note 1 - Nature of Business & Organization

	BioNeutral Group, Inc. (the “Company”) is a specialty chemical corporation seeking to develop and commercialize a novel combinational chemistry-based technology which it believes, in certain circumstances, may neutralize harmful environmental contaminants, toxins and dangerous micro-organisms including bacteria, viruses and spores. The Company currently operates its business through its subsidiary, BioNeutral Laboratories Corporation USA (“BioNeutral Laboratories” or “BioLabs”), a corporation organized in Delaware in 2003. The Company was incorporated in the State of Nevada on April 10, 2007 under the name “Moonshine Creations, Inc.,” and changed its name to “BioNeutral Group, Inc.” on December 22, 2008.

	On January 30, 2009, the Company entered into a share exchange agreement (the “Share Exchange Agreement”) with BioNeutral Laboratories pursuant to which it agreed to issue to the shareholders of BioNeutral Laboratories 45,000,000 shares of our common stock. Upon completion of this transaction, the former shareholders of BioNeutral Laboratories became the majority stockholders of the Company. Accordingly, the transaction was accounted for as a reverse merger and recapitalization of BioNeutral Group, Inc.

Liquidity_and_Financial_Condit

Liquidity and Financial Condition	3 Months Ended
Liquidity and Financial Condition	Jan. 31, 2014
Liquidity and Financial Condition [Abstract]	'
Liquidity and Financial Condition	'
	Note 2 – Liquidity and Financial Condition

	The Company's unaudited condensed consolidated financial statements are prepared using generally accepted accounting principles applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has had no significant revenues and has generated losses from operations. In order to continue as a going concern and achieve a profitable level of operations, the Company will need, among other things, additional capital resources and to develop a consistent source of revenues. The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish its strategic plan and/or recognize revenue from its intangible assets and eventually attain profitable operations. The accompanying unaudited condensed consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. There can be no assurance the Company will be able to continue as a going concern.
	At January 31, 2014, the Company had negative working capital of $2,987,203. For the three months ended January 31, 2014 the Company incurred a net loss of $820,640 and since inception has an accumulated deficit of $58,640,453. For the same period in 2013, the Company’s net loss was $761,380. The Company anticipates it will experience a net loss in fiscal 2014 as it continues to pursue markets for the sale and distribution of its products and development of access to global markets.

	The Company had $1,244 of cash at January 31, 2014. Cash used by operations for the three months ended January 31, 2014 was $198,458. The principal uses of funds were for consulting services supporting the development of our business plan, legal and accounting fees in connection with being a public company and daily operations of the business, including rent, travel and laboratory costs.
	During the three months ended January 31, 2014, the Company raised $199,000 of cash from the issuance of convertible debentures to fund operations.

	On December 12, 2012 the Company issued a convertible promissory note to JMJ financial in the amount of $250,000 of which it received payments through the date of this report of $190,000. It expects to receive additional payments from JMJ under the note at various intervals during the calendar year 2014.

	While the Company has been able to use proceeds from the issuance of convertible promissory notes to fund a substantial balance of its operating costs, it does not expect that its funds will be sufficient to meet its anticipated needs through February 1, 2015 and it will need to raise additional capital during fiscal 2014 to fund the full costs associated with its growth and development.

	The Company believes that it will be able to generate significant sales by the fourth quarter of 2014 providing for sufficient cash flows to supplement its equity financing based on its current plans. If it’s able to execute its plan, the Company can begin to accumulate cash reserves. There is no assurance however that its funds will be sufficient to meet its anticipated needs through its fiscal year 2014, and it may need to raise additional capital during fiscal 2014 to fund the full costs associated with its growth and development. The Company believes that it will require approximately $2,000,000 in additional capital to achieve its goals. There can be no assurances that it will be successful in raising additional capital on favorable terms if at all. If the Company is unable to secure additional capital, it may be required to curtail its business development initiatives, impair its intellectual property and take additional measures to reduce costs in order to conserve cash.
	These conditions raise substantial doubt about the Company’s ability to continue as a going concern. Accordingly, the accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplates continuation of the Company as a going concern and the realization of assets and the satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the financial statements do not necessarily purport to represent realizable or settlement values. The unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Summary_of_Significant_Account

Summary of Significant Accounting Policies

3 Months Ended

Jan. 31, 2014

Summary of Significant Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Note 3 - Summary of Significant Accounting Policies

Basis of Presentation

The condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial statements and with Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission (the “SEC”). Accordingly, they do not contain all the information and footnotes required by GAAP for annual financial statements. The condensed consolidated financial statements include the accounts of the Company and its majority owned subsidiary. All significant intercompany balances and transactions have been eliminated in consolidation. In the opinion of the Company’s management, the accompanying condensed consolidated financial statements contain all the adjustments necessary (consisting only of normal recurring accruals) to make the financial position of the Company as of January 31, 2014 and the results of operations and cash flows for the three months ended January 31, 2014 and 2013 not misleading. The unaudited condensed consolidated financial statements for the quarterly periods ended January 31, 2014, and 2013 are not necessarily indicative of the operating results for the full year and it is suggested that these unaudited condensed consolidated financial statements be read in conjunction with the audited financial statements for the years ended October 31, 2013 and 2012 as contained in the Form 10-K filed on February 13, 2014.

Revenue recognition

The revenue recorded is presented net of sales and other taxes we collect on behalf of governmental authorities and includes shipping and handling costs, which generally are included in the list price to the customer. Our policy is to recognize revenue in accordance with SEC Staff Accounting Bulletin No. 104 based on when (i) persuasive evidence of an arrangement exists, (ii) delivery or performance has occurred, (iii) the fee is fixed or determinable, and (iv) collectability of the sale is reasonably assured, which is normally the date the product is shipped.

Accounts Receivable and Allowance for Doubtful Accounts

Accounts receivable are stated at the amount the Company expects to collect. The Company provides an allowance for doubtful accounts equal to the estimated uncollectible amounts. The Company’s estimate is based on historical collection experience and a review of the current status of trade accounts receivable. It is reasonably possible that the Company’s estimate of the allowance for doubtful accounts will change. Accounts receivable are presented net of an allowance for doubtful accounts which was not material at both January 31, 2014 and October 31 2013.

Cash and Cash Equivalents

The Company considers all highly liquid investments with a maturity of six months or less when purchased to be cash equivalents. For financial statement purposes, investments in money market funds are considered a cash equivalent and are included in cash and cash equivalents. The Company maintains its cash and cash equivalents at high credit quality institutions, with balances, at times, in excess of federally insured limits. As of January 31, 2014, the Company did not exceed the federally insured limits. Management believes that the financial institution that holds our deposits are financially sound and therefore pose minimal credit risk. At January 31, 2014 and October 31 2013, the Company did not hold any cash equivalents.

Inventory

Inventories are stated at the lower of cost or market determined by the first-in, first-out method. In the normal course of business, when a customer places an order, the Company will place an order for manufacturing with its contract manufacturer. Inventory consists of finished goods and raw materials, both of which are immaterial and warehoused at our contract manufacturer.

Non-Controlling Interest

A non-controlling interest was created as a result of the Company’s reorganization and recapitalization with a public shell corporation. The non-controlling interest arose because the Company’s records indicated that initially 14% of the shareholders of the accounting acquirer in the transaction, BioLabs, did not participate in the exchange of their shares of common stock of BioLabs for shares of common stock of the Company. In all material respects, the shares of the Company and the shares of the common stock of BioLabs included in the non-controlling interest represent different legal instruments conveying mirror ownership claims to the same underlying net assets and operations, as reflected in these unaudited condensed consolidated financial statements.

Use of Estimates

The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates. These estimates and assumptions include valuing equity securities, share based payment arrangements, deferred taxes and related valuation allowances and estimating the fair value of long-lived assets to assess whether impairment charges may be necessary. Certain of our estimates, could be affected by external conditions, including those unique to our industry, and general economic conditions. It is possible that these external factors could have an effect on our estimates that could cause actual results to differ from our estimates. The Company re-evaluates all of its accounting estimates at least quarterly based on these conditions and record adjustments when necessary.

Fair Value Measurements

The Company adopted the provisions of ASC Topic 820, “Fair Value Measurements and Disclosures”, which defines fair value as used in numerous accounting pronouncements, establishes a framework for measuring fair value and expands disclosure of fair value measurements.

The estimated fair value of certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments. The carrying amounts of our long-term credit obligations approximate fair value because the effective yields on these obligations, are comparable to rates of returns for instruments of similar credit risk.

ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:

Level 1 — quoted prices in active markets for identical assets or liabilities

Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable

Level 3 — inputs that are unobservable (for example cash flow modeling inputs based on assumptions)

Financial liabilities measured at fair value on a recurring basis are summarized below:

Fair value measurements at January 31, 2014

Quoted prices in

active markets for

Significant

observable

other

unobservable

identical assets

inputs

Total

(Level 1)

(Level 2)

(Level 3)

Derivative liability

156,913

The derivative liabilities are measured at fair value using quoted market prices and estimated volatility factors based on historical quoted market prices for the Company’s common stock, and are classified within Level 3 of the valuation hierarchy.

The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial liabilities that are measured at fair value on a recurring basis:

January 31,

October 31,

2014

2013

(unaudited)

Beginning Balance

129,425

Aggregate fair value of derivative issued

36,000

337,221

Issuance date charge for difference between fair value and note proceeds

171,389

Change in fair value of derivative included in results of operations

(8,512

)

(379,185

)

Ending Balance

156,913

129,425

Convertible Instruments

The Company evaluates and accounts for conversion options embedded in convertible instruments in accordance with ASC 815 “Derivatives and Hedging Activities.”

Applicable GAAP requires companies to bifurcate conversion options from their host instruments and account for them as freestanding derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.

Stock-Based Compensation

The Company recognizes compensation expense for stock-based compensation in accordance with ASC Topic 718. For employee stock-based awards, the Company calculates the fair value of the award on the date of grant using the Black-Scholes method for stock options and the quoted price of its common stock for unrestricted shares; the expense is recognized over the service period for awards expected to vest. For non-employee stock-based awards, the Company calculate the fair value of the award on the date of grant in the same manner as employee awards, however, the awards are revalued at the end of each reporting period and the pro rata compensation expense is adjusted accordingly until such time the nonemployee award is fully vested, at which time the total compensation recognized to date equals the fair value of the stock-based award as calculated on the measurement date, which is the date at which the award recipient’s performance is complete. The estimation of stock-based awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from original estimates, such amounts are recorded as a cumulative adjustment in the period estimates are revised. The Company considers many factors when estimating expected forfeitures, including types of awards, employee class, and historical experience.

Net income (loss) per share

The Company utilizes FASB ASC 260, Earnings per Share, to calculate gain or loss per share. Basic gain or loss per share is computed by dividing the gain or loss available to common stockholders (as the numerator) by the weighted-average number of shares of common stock outstanding (as the denominator). Diluted gain or loss per share is computed similar to basic gain or loss per share except that the denominator is increased to include the number of additional shares of common stock that would have been outstanding if all potential common stock (including common stock equivalents) had all been issued, and if such additional shares of common stock were dilutive. Under FASB ASC 260, if the additional shares of common stock are not dilutive, they are not added to the denominator in the calculation. Where there is a loss, the inclusion of additional shares of common stock is anti-dilutive (since the increased number of shares reduces the per share loss available to common stock holders). The Company incurred a loss for the three months ended January 31, 2014 and 2013 therefore, common stock equivalents have been excluded from the calculation of diluted loss per share.

The following table outlines the common stock equivalents outstanding as of January 31, 2014 and 2013.

1/31/14

1/31/13

Convertible Series A Preferred Stock – Non Controlling Interest

594,930

Convertible Series B Preferred Stock

6,686,375

Convertible Series C Preferred Stock

7,010,125

Convertible Series D Preferred Stock

16,031,375

17,006,375

Convertible Loans

1,960,266,081

25,003,347

1,990,588,886

56,301,152

The Convertible Series A Preferred shares are currently held by the Non-Controlling interests until such time as they are converted into the Company’s common shares.

Recent Accounting Pronouncements

The FASB has issued ASU No. 2013-11, Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists (a consensus of the FASB Emerging Issues Task Force). U.S. GAAP does not include explicit guidance on the financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. The amendments in this ASU state that an unrecognized tax benefit, or a portion of an unrecognized tax benefit, should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward, except as follows. To the extent a net operating loss carryforward, a similar tax loss, or a tax credit carryforward is not available at the reporting date under the tax law of the applicable jurisdiction to settle any additional income taxes that would result from the disallowance of a tax position or the tax law of the applicable jurisdiction does not require the entity to use, and the entity does not intend to use, the deferred tax asset for such purpose, the unrecognized tax benefit should be presented in the financial statements as a liability and should not be combined with deferred tax assets. This ASU applies to all entities that have unrecognized tax benefits when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists at the reporting date. The amendments in this ASU are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. For nonpublic entities, the amendments are effective for fiscal years, and interim periods within those years, beginning after December 15, 2014. Early adoption is permitted. The amendments should be applied prospectively to all unrecognized tax benefits that exist at the effective date. Retrospective application is permitted. The adoption of this standard is not expected to have a material impact on the Company’s results of operations, cash flows or financial position.

Intellectual_Property

Intellectual Property	3 Months Ended
Intellectual Property	Jan. 31, 2014
Intellectual Property [Abstract]	'
Intellectual Property	'
	Note 4 – Intellectual Property

	The Company has several patent applications pending regarding proprietary chemical formulations that the Company believes are capable of neutralizing noxious chemicals and eliminating harmful microbes. The Company capitalized the costs of acquired technology, know-how and trade secrets and identifiable costs incurred to develop file and defend the Company’s Intellectual Property and new patent or provisional patent applications (collectively “Intellectual Property”) in accordance with FASB ASC 350. Periodic gross carrying amounts and related accumulated amortization were as follows:

		1/31/14			10/31/13
	Gross Carrying Amount	$	15,256,688		$	15,256,688
	Accumulated Amortization		(6,184,371	)		(6,007,190	)
	Net Carrying Amount	$	9,072,317		$	9,249,498

	The Company follows FASB ASC 350-30-35 and amortizes the costs of its Intellectual Property over the shorter of its specific useful life, or 20 years. The Company is amortizing its Intellectual Property over 20 years, with no anticipated residual value. Amortization expense for the three months ended January 31, 2014 and 2013 was $177,181 and $177,181, respectively.

	Estimated amortization expense is as follows

	10/31/2014 (Remaining)		531,542
	10/31/15		708,723
	10/31/16		708,723
	10/31/17		708,723
	10/31/18		708,723

	The Intellectual Property is evaluated annually for recoverability pursuant to FASB ASC 350-30-35-14 and related guidance in ASC 360-10-35-17 thru 35-35. An impairment loss is recognized if the asset is determined not to be recoverable and its carrying amount exceeds its fair value. During its annual impairment testing, the Company did not identify an impairment loss.

Related_Party_Payables

Related Party Payables	3 Months Ended
Related Party Payables	Jan. 31, 2014
Related Party Payables [Abstract]	'
Related Party Payables	'
	Note 5 - Related Party Payables

	During the three months ended January 31, 2014 and 2013, the Company recorded interest expense of $518 and $518, respectively, on promissory notes entered into with former members of the Board of Directors who resigned their positions with the Company on January 29, 2009.

Stock_Based_Compensation

Stock Based Compensation	3 Months Ended
Stock Based Compensation	Jan. 31, 2014
Stock Based Compensation [Abstract]	'
Stock Based Compensation	'
	Note 6 - Stock Based Compensation

	The Company issues shares of its common stock to employees and non-employees as compensation for services provided. Stock based compensation related to employees is accounted for in accordance with FASB ASC 718-10 and ASC 505-50 for non-employees. All shares issued during fiscal years 2013 and 2012 were fully vested upon grant of the shares or no later than the respective year end dates.

	Employees and Board Members

	Measurement of compensation cost related to shares of common stock issued to employees is based on the grant date fair value of the shares. Fair value was determined through the use of quoted prices in the trading market for the Company’s shares (OTCBB) or arms-length exchanges of shares for cash in private transactions, in periods that quoted market prices were not available.

	On December 11, 2013 the Company canceled 1,705,152 shares of its S-8 registered common stock which had been issued to an employee for compensation and out of pocket expenses incurred in fiscal 2013 of $72,263.

Stockholders_Equity_and_NonCon

Stockholders' Equity (and Non-Controlling Interest)	3 Months Ended
	Jan. 31, 2014
Stockholders' Equity (And Non-Controlling Interest) [Abstract]	'
Stockholders' Equity (and Non-Controlling Interest)	'
	Note 7 – Stockholders’ Equity (and Non-Controlling Interest)

	Common Stock

	On December 18, 2013, the Company filed a Schedule 14C Information Statement with the SEC to notify the stockholders of the Company of Management’s plan to increase the number of authorized shares of common stock from one billion (1,000,000,000) to four billion (4,000,000,000) shares with the Secretary of State of Nevada. At a meeting held on November 26, 2013, and in conjunction with a unanimous consent of the Board on December 11, 2013, the Board authorized management to increase the number of shares authorized to four billion shares. The additional three billion (3,000,000,000) shares of Common Stock so authorized will be available for issuance by the Board for stock splits or stock dividends, acquisitions, raising additional capital, stock options or other corporate purposes. The additional shares of Common Stock could be used for potential strategic transactions, including, among other things, acquisitions, strategic partnerships, joint ventures, restructurings, business combinations and investments, although there are no immediate plans to do so. Assurances cannot be provided that any such transactions will be consummated on favorable terms or at all, that they will enhance stockholder value or that they will not adversely affect the Company's business or the trading price of the Common Stock. The purposes for increasing the authorized shares include providing available shares for (i) the exercise of all outstanding options; (ii) the conversion of outstanding convertible promissory notes and deferred compensation agreements; (iii) the conversion of the Series A, B, C and D Convertible Preferred Stock; (iv) future issuances of stock options pursuant to employees; and (v) issuances to satisfy conversions of future convertible debt or convertible preferred stock. We mailed the Notice of Stockholder Action by Written Consent to the Stockholders on December 31, 2013. The authorized share increase became effective on the date that the Company filed the Certificate of Amendment to the Amended Certificate of Incorporation of the Company (the "Amendment") with the Secretary of State of the State of Nevada. The Company filed the Amendment with the Secretary of State of the State of Nevada on January 2, 2014.

	On December 19, 2013, the Company issued 11,000,000 shares of its restricted common stock to a consulting firm for marketing fees of $10,000. The shares were valued and issued at $.0009 per share based on the prevailing quotation prices for the Company's stock.

	On November 21, 2013, the Company issued 1,000,000 shares of its common stock to Randy McNeil pursuant to a stock purchase agreement with Mr. McNeil on September 12, 2013 for $5,000. The purchase price per share of the common stock is $.005 which was equal to the closing trading price of the Company’s common stock on September 10, 2013.

	On November 21, 2013, the Company issued 1,466,276 shares of its common stock to Bernie Casamento pursuant to a stock purchase agreement with Mr. Casamento on August 16, 2013 for $10,000. The purchase price per share of the common stock was $.0068 which was equal to the average closing trading price of the Company’s common stock for the five (5) preceding days of the closing on August 16, 2013.

	On November 21, 2013, the Company issued 1,466,276 shares of its common stock to Bob Rutherford pursuant to a stock purchase agreement with Mr. Rutherford entered into on August 16, 2013 for $10,000. The purchase price per share of the common stock was $.0068 which is equal to the average closing trading price of the Company’s common stock for the five (5) preceding days of the closing on August 16, 2013.

	On November 13, 2013, the Company issued 24,000,000 to reduce certain outstanding accounts payable. The shares were valued at $.0013 representing the approximate trading price of the Company’s common stock at the time of the issuance.

	During the three months ended January 31, 2014, the Company issued 189,900,000 shares of its common stock to JMJ Financial for conversion of principal and unpaid interest of $61,474.

	During the three months ended January 31, 2014, the Company issued 198,072,984 shares of common stock to Asher Enterprises to convert short-term convertible promissory notes in the aggregate amount of $65,450.

	During the three months ended January 31, 2014, the Company issued 120,853,516 shares of common stock to GEL Properties, LLC (“GEL”) to convert short-term convertible promissory notes in the aggregate of $60,632.

	Non-Controlling Interest

	In connection with the reverse acquisition disclosed in Note 1, initially approximately 14% of BioLabs’ common shareholders did not participate in the exchange of their shares of BioLabs common stock for shares of common stock of the Company. Those shareholders are recognized as a non-controlling interest in the Company’s condensed consolidated financial statements in accordance with FASB ACS 805-40-25-2. The assets, liabilities and operations underlying the shares of BioLabs and the Company are identical. However, the shares representing ownership of the Company reflect the combined entity after the Share Exchange transaction, while BioLabs shares included in the non-controlling interest held by the non-controlling interest represent ownership of that legal entity.

	Non-Controlling Interest at October 31, 2010	$	570,301
	Non-Controlling Interest Converted		(25	)
	Non-Controlling interest Share of Net Loss for the Year ended October 31, 2011		(241,693	)
	Non-Controlling Interest at October 31, 2011		328,583
	Non-Controlling interest Share of Net Loss for the Year ended October 31, 2012		(219,981	)
	Non-Controlling Interest at October 31, 2012		108,602
	Non-Controlling interest Share of Net Loss for the Year ended October 31, 2013		(269,303	)
	Non-Controlling Interest at October 31, 2013		(160,701	)
	Non-Controlling interest Share of Net Loss for the three months ended January 31, 2014		(69,262	)
	Non-Controlling Interest at January 31, 2014	$	(229,963	)

	The Series A Preferred Stock is not recognized in the Non-Controlling Interest. If the 59,493 shares of preferred stock were fully converted into shares of BioLabs common stock and Preferred Shareholders did not elect to exchange those shares for Company common stock, the Non-Controlling interest would be 8.44% as of January 31, 2014 and October 31, 2013.

Notes_Payable

Notes Payable	3 Months Ended
Notes Payable	Jan. 31, 2014
Notes Payable [Abstract]	'
Notes Payable	'
	Note 8 – Notes Payable

	On January 14, 2014, the Company issued a convertible promissory note to GEL in the amount of $25,444, due on January 14, 2015, which bears interest at 6% per annum. GEL is entitled, at its option, at any time after the requisite rule 144 holding period, to convert all or any amount of the principal face amount of this Note then outstanding into shares of the Company's common stock without restrictive legend of any nature, at a conversion price for each share of Common Stock equal to 65% of the lowest closing bid price of the Common Stock. In connection with the issuance of the convertible promissory note to GEL, GEL purchased a promissory note issued to Ray Dunning on January 31, 2013 in the amount of $23,600 plus accrued and unpaid interest. During the three months ended January 31, 2014 the Company received three notices of conversion from GEL, and pursuant to those notices issued 27,500,000 shares of common stock to settle loan proceeds in the collective amount of $13,387.

	On January 14, 2014, the Company issued a convertible promissory note to GEL in the amount of $25,276, due on January 14, 2015, which bears interest at 6% per annum. GEL is entitled, at its option, at any time after the requisite rule 144 holding period, to convert all or any amount of the principal face amount of this Note then outstanding into shares of the Company's common stock without restrictive legend of any nature, at a conversion price for each share of Common Stock equal to 65% of the lowest closing bid price of the Common Stock. In connection with the issuance of the convertible promissory note to GEL, GEL purchased a promissory note issued to Ray Dunning on February 28, 2013 in the amount of $23,600 plus accrued and unpaid interest.
	On January 14, 2014, the Company issued a convertible promissory note to GEL in the amount of $30,000, due on January 14, 2015, which bears interest at 6% per annum. GEL is entitled, at its option, at any time after the requisite rule 144 holding period, to convert all or any amount of the principal face amount of this Note then outstanding into shares of the Company's common stock without restrictive legend of any nature, at a conversion price for each share of Common Stock equal to 65% of the lowest closing bid price of the Common Stock.

	On January 8, 2014, the Company issued a convertible promissory note to GEL in the amount of $23,600, due on January 8, 2015, which bears interest at 6% per annum. GEL is entitled, at its option, at any time after the requisite rule 144 holding period, to convert all or any amount of the principal face amount of this Note then outstanding into shares of the Company's common stock without restrictive legend of any nature, at a conversion price for each share of Common Stock equal to 65% of the lowest closing bid price of the Common Stock. In connection with the issuance of the convertible promissory note to GEL, GEL also purchased a promissory note issued to Ray Dunning on April 30, 2013 in the amount of $23,600. During the three months ended January 31, 2014 the Company received two notices of conversion from GEL, and pursuant to those notices issued 51,914,879 shares of common stock to settle the loan amount of $23,600.

	On January 8, 2014, the Company issued a convertible promissory note to GEL in the amount of $20,000, due on January 8, 2015, which bears interest at 6% per annum. GEL is entitled, at its option, at any time after the requisite rule 144 holding period to convert all or any amount of the principal face amount of this Note then outstanding into shares of the Company's common stock without restrictive legend of any nature, at a conversion price for each share of Common Stock equal to 65% of the lowest closing bid price of the Common Stock.

	On January 2, 2014, the Company issued a convertible promissory note (the “Hanafin Note”) to Ben Hanafin, a member of the Company’s Board of Directors, in the amount of $5,000. The Hanafin Note is due on January 2, 2015, and bears interest at 18% per annum. Mr. Hanafin has the right to convert the principal and interest into the Company’s common stock at a conversion price equal to 50% of the average closing price of the Company’s common stock for the 10 preceding days of the Maturity Date of January 2, 2015.

	On December 18, 2013, the Company issued a convertible promissory note to GEL in the amount of $23,600, due on December18, 2014, which bears interest at 6% per annum. GEL is entitled, at its option, at any time after the requisite rule 144 holding period, to convert all or any amount of the principal face amount of this Note then outstanding into shares of the Company's common stock without restrictive legend of any nature, at a conversion price for each share of Common Stock equal to 65% of the lowest closing bid price of the Common Stock. In connection with the issuance of the convertible promissory note to GEL, GEL purchased a promissory note issued to Ray Dunning on March 29, 2013 in the amount of $23,600. Up through and including the date of this report the Company has received conversion notices from GEL representing $18,000 of principal and interest due to GEL. During the three months ended January 31, 2014 the Company received ten notices of conversion from GEL, and pursuant to those notices issued an aggregate of 41,438,636 shares of common stock to settle the loan.

	On December 18, 2013, the Company issued a convertible promissory note to GEL in the amount of $20,000, due on December18, 2014, which bears interest at 6% per annum. GEL is entitled, at its option, at any time after the requisite rule 144 holding period, to convert all or any amount of the principal face amount of this Note then outstanding into shares of the Company's common stock without restrictive legend of any nature, at a conversion price for each share of Common Stock equal to 65% of the lowest closing bid price of the Common Stock.

	On November 11, 2013, the Company issued a Promissory Note to Herb Kozlov, a shareholder of the Company (the “Kozlov Note”), for the satisfaction of a promissory note issued by the Company to Mr. Kozlov on December 6, 2010. Pursuant to the Kozlov Note, the Company promises to pay $75,000.00 plus any accrued and unpaid interest on June 1, 2014. Interest will accrue at the rate of fourteen (14%) per annum. Mr. Kozlov will have the right to receive payment of the Kozlov Note in shares of common stock of the Company at the lower of $.03 per share, or the closing price of such shares on the day proceeding the date when the notice of full or partial conversion is tendered.

	On November 5, 2013, the Company issued a convertible promissory note (the “Machinist Note”) to Robert Machinist, a member of the Company’s Board of Directors, in the amount of $25,000. The Machinist Note is due on November 4, 2014, and bears interest at 18% per annum. Mr. Machinist has the right to convert the principal and interest into the Company’s common stock at a conversion price equal to 50% of the average closing price of the Company’s common stock for the 10 preceding days of the Maturity Date of November 4, 2014.

	On November 4, 2013 the Company received loan proceeds from Michael Francis in the amount of $25,000. Mr. Francis and the Company agreed to include the additional $25,000 of proceeds to the Francis Modification.

	On December 12, 2012, BioNeutral Group, Inc. (the “Company”) issued a promissory note (the “JMJ Note”) in the principal amount of $250,000 to JMJ Financial (“JMJ”), of which $190,000 has been received through the date of this report. The maturity date is one year from the date of each payment. The JMJ Note is interest free if repaid within 90 days and if not paid within 90 days it bears interest at 10%. The principal and any accrued interest are convertible into the Company’s common stock at the lower of $.09 per share of 70% of the lowest trade price in the 25 days prior to conversion. JMJ has piggyback registration rights with respect to the shares into which the JMJ Note is convertible. During the three months ended January 31, 2014 the Company received eight notices of conversion from JMJ, and pursuant to those notices issued an aggregate of 189,900,000 shares of common stock to settle loan proceeds in the collective amount of $61,474. At January 31, 2014 the JMJ aggregate loan balance was $81,040 including accrued interest of $16,667.

	Derivative Financial Instrument

	The Company evaluates and accounts for conversion options embedded in its convertible instruments in accordance with ASC 815, Derivatives and Hedging which requires issuers of financial statements to make a determination as to whether (1) an embedded conversion meets the definition of a derivative in its entirety and (2) the derivative would qualify for a scope exception to derivative accounting, which includes evaluating whether the embedded derivative would be considered indexed to the issuer’s own stock.

	ASC 815 generally provides three criteria that, if met, require companies to bifurcate conversion options from their host instruments and account for them as separate derivatives in the event such derivatives would not be classified in stockholders’ equity if they were free standing. These three criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under other applicable US GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument subject to the requirements of ASC 815. ASC 815 also provides for an exception to this rule if a debt host instrument is deemed to be a conventional debt instrument.

	The Company evaluated the conversion option embedded in its Convertible notes in accordance with the provisions of ASC 815 and determined that on the conversion date, the conversion option will have all of the characteristics of a derivative in its entirety and does not qualify for an exception to the derivative accounting rules. Specifically, because the exercise price of the conversion option is not fixed at any time during the term of the note. Accordingly, the embedded conversion option in the Convertible notes are classified as derivative liabilities at the conversion dates and are marked to market through earnings at the end of each reporting period. The fair value of the conversion option was determined using the intrinsic value method which the Company believes approximate the results obtained using the Binomial Lattice model. The gross proceeds of Convertible notes issued during the three months ended January 31, 2014 were recorded net of a discount of $36,000 related to the derivative liability. The debt discount will be charged to amortization of debt discount ratably over the term of the Convertible notes. The Company recorded an amortization of the debt discount in the amount of $40,424 for the three months ended January 31, 2014.

Commitments_Contingencies

Commitments & Contingencies	3 Months Ended
Commitments & Contingencies	Jan. 31, 2014
Commitments and Contingencies [Abstract]	'
Commitments and Contingencies	'
	Note 9 – Commitments & Contingencies

	Litigation

	On November 26, 2012, the Company filed a complaint against Raj Pamani, a shareholder and former director of the Company in the Superior Court of New Jersey Essex County: Chancery Division (“the Complaint”). Included also as defendants were several entities to which in 2009 the Company awarded approximately 13 million shares of its common stock in consideration for consulting contracts which the Company has concluded were fraudulently induced and were later deemed to be worthless (the “Defendant Entities”). By causing the Company to enter into the contracts to its detriment in favor of Mr. Pamani’s and the Defendant Entities self-enrichment, the Company seeks to recover damages incurred from the actions of Mr. Pamani and the Defendant Entities as a result of self-dealing, breach of fiduciary duty, breach of loyalty and fraud. As this matter unfolds, the Company may pursue and recover damages incurred from other parties that come to its attention for their participation.

	On October 1, 2009, the SEC issued a formal order of investigation to the Company regarding possible securities laws violations by us and other persons. The investigation concerns the process by which the Company became a publicly traded entity, trading in the Company’s shares, and disclosure and promotion of developments in the Company’s business. The SEC has requested that the Company deliver certain documents to the SEC. The Company has, and will continue to fully cooperate with the SEC with respect to its investigation.

	The Company has incurred, and expects to continue to incur, significant costs in responding to such investigation. Any adverse findings by the SEC in connection with such investigation could have a material adverse impact on the Company's business, including the Company's ability to continue to operate as a publicly traded company.

	In April 2005, the Company filed in the US Patent and Trademark Office (the “USPTO”) an application for the registration of the trademarks BioNeutral™, Ogiene® and Ygiene™, based on its intent to use each of these marks in commerce. In April 2006, the USPTO issued notices of allowance signifying that each of these trademarks was entitled to registration after timely submission of statements of use, including evidence that such trademarks have been properly used in commerce. From June through November of 2008, however, the Company’s applications for each of these trademarks were declared abandoned by the USPTO, since the Company inadvertently failed to timely file the appropriate statements of use with respect to each trademark within the six-month period from the date the USPTO issued the respective notices of allowance. In July 2009, the Company again submitted applications for each of these trademarks as well as the Company’s tagline SCIENCE TO SAVE LIVES & PROTECT THE ENVIRONMENT™; however, the Company learned that PURE Bioscience, a company focused on the development and commercialization of bioscience products, had filed application for the registration of the trademarks BioNeutral™ and Ygiene™ prior to the Company’s resubmission of its applications. Subsequently in 2011, the Company received trademark registration from the USPTO for Ygiene™, Ogiene™ and the Company’s taglineSCIENCE TO SAVE LIVES & PROTECT THE ENVIRONMENT™. The Company intends to pursue with the Trademark Trial and Appeal Board an opposition to PURE Bioscience's application with respect to BioNeutral™. The Company cannot assure you that it will be successful with such opposition on a timely basis, if at all. In May 2011, the Company received notice that PURE Bioscience filed a petition with the USPTO for cancellation of the Company’s Ygiene™ registration. On November 14, 2013 the USPTO issued an order for dismissal of PURE Bioscience’s petition to for cancellation of the Company’s Ygiene™ registration.

	Other than the foregoing, the Company is not a party to, and none of the Company’s property is the subject of, any pending legal proceedings other than routine litigation that is incidental to the Company’s business.

	Other Contingencies

	Approximately 6 million shares issued in the Share Exchange were issued by the then transfer agent to stockholders of BioLabs for whom the Company does not have records as having consented to the Share Exchange. The Company currently holds approximately 91% of the outstanding interests in its subsidiary, BioLabs. The Company did not receive consents to the Share Exchange from all common and preferred shareholders of BioLabs, and the Company has accounted for those shareholders who did not sign consents as holders of the remaining 9% outstanding interests in BioLabs. The Share Exchange consents did not specify the number of shares of BioLabs common stock to be exchanged by the consenting shareholder and did not affirmatively make the representation and warranties to be made by our stockholders as set forth in the Share Exchange. In light of such omissions, there can be no assurances that a shareholder will not challenge the validity of its consent and request a rescission offer in respect of shares of common stock issued to such person. There can also be no assurances that in light of the content of such Shareholder consent, the Company had a basis for a valid private placement of its common stock issued in the Share Exchange, which if such were the case, may negatively affect our status as a publicly traded company.

	In addition, the Company believes that the shareholders who consented to the Share Exchange and were issued shares of Company common stock but failed to deliver the stock certificates representing their shares of common stock and Series A Preferred Stock of BioLabs may claim they also have an ownership interest in BioLabs. Although the Company would challenge any such claims, it cannot assure investors that it would prevail, in which case the Company’s percentage ownership interest in BioLabs would decrease.

Subsequent_Events

Subsequent Events	3 Months Ended
Subsequent Events	Jan. 31, 2014
Subsequent Events [Abstract]	'
Subsequent Events:	'
	Note 10 - Subsequent Events:

	Subsequent events have been evaluated through the date the financial statements were issued. All appropriate subsequent event disclosures, if any, have been made in the notes to the consolidated financial statements.

	Subsequent to January 31, 2014 the Company received notices of conversion from JMJ, Asher and GEL, and pursuant to those notices issued an aggregate of 239,832,360 shares of common stock to settle loan proceeds in the aggregate amount of $103,031.
	On February 10, 2014, the Company issued a convertible promissory note to GEL in the amount of $44,071.23, due on February 10, 2015, which bears interest at 6% per annum. GEL is entitled, at its option, at any time after the requisite rule 144 holding period, to convert all or any amount of the principal face amount of this Note then outstanding into shares of the Company's common stock without restrictive legend of any nature, at a conversion price for each share of Common Stock equal to 65% of the lowest closing bid price of the Common Stock. In connection with the issuance of the convertible promissory note to GEL, GEL purchased a promissory note issued to Ray Dunning on June 30, 2013 from the Company in the amount of $42,000 plus accrued and unpaid interest.

	On February 10, 2014, the Company issued a convertible promissory note to GEL in the amount of $25,000, due on February 10, 2015, which bears interest at 6% per annum. GEL is entitled, at its option, at any time after the requisite rule 144 holding period, to convert all or any amount of the principal face amount of this Note then outstanding into shares of the Company's common stock without restrictive legend of any nature, at a conversion price for each share of Common Stock equal to 65% of the lowest closing bid price of the Common Stock.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)

3 Months Ended

Jan. 31, 2014

Summary of Significant Accounting Policies [Abstract]

Basis of Presentation

Revenue recognition

Accounts Receivable and Allowance for Doubtful Accounts

Cash and Cash Equivalents

Inventory

Non-Controlling Interest

Use of Estimates

Fair Value Measurements

Level 1 — quoted prices in active markets for identical assets or liabilities

Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable

Level 3 — inputs that are unobservable (for example cash flow modeling inputs based on assumptions)

Financial liabilities measured at fair value on a recurring basis are summarized below:

Fair value measurements at January 31, 2014

Quoted prices in

active markets for

Significant

observable

other

unobservable

identical assets

inputs

Total

(Level 1)

(Level 2)

(Level 3)

Derivative liability

156,913

The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial liabilities that are measured at fair value on a recurring basis:

January 31,

October 31,

2014

2013

(unaudited)

Beginning Balance

129,425

Aggregate fair value of derivative issued

36,000

337,221

Issuance date charge for difference between fair value and note proceeds

171,389

Change in fair value of derivative included in results of operations

(8,512

)

(379,185

)

Ending Balance

156,913

129,425

Convertible Instruments

The Company evaluates and accounts for conversion options embedded in convertible instruments in accordance with ASC 815 “Derivatives and Hedging Activities.”

Stock-Based Compensation

Net income (loss) per share

The following table outlines the common stock equivalents outstanding as of January 31, 2014 and 2013.

1/31/14

1/31/13

Convertible Series A Preferred Stock – Non Controlling Interest

594,930

Convertible Series B Preferred Stock

6,686,375

Convertible Series C Preferred Stock

7,010,125

Convertible Series D Preferred Stock

16,031,375

17,006,375

Convertible Loans

1,960,266,081

25,003,347

1,990,588,886

56,301,152

The Convertible Series A Preferred shares are currently held by the Non-Controlling interests until such time as they are converted into the Company’s common shares.

Recent Accounting Pronouncements

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	3 Months Ended
Summary of Significant Accounting Policies (Tables)	Jan. 31, 2014
Summary of Significant Accounting Policies [Abstract]	'
Summary of Financial liabilities measured at fair value on recurring basis	'
		Fair value measurements at January 31, 2014
					Quoted prices in
					active markets for		Significant		Significant
					observable		other		unobservable
					identical assets		inputs		inputs
		Total			(Level 1)		(Level 2)		(Level 3)
	Derivative liability	$	156,913						$	156,913
Summary of changes in fair value of Level 3 financial liabilities measured at fair value on recurring basis	'
		January 31,				October 31,
		2014				2013
		(unaudited)

	Beginning Balance	$	129,425			$	-
	Aggregate fair value of derivative issued		36,000				337,221
	Issuance date charge for difference between fair value and note proceeds		-				171,389
	Change in fair value of derivative included in results of operations		(8,512	)			(379,185	)

	Ending Balance	$	156,913			$	129,425

Summary of common stock equivalents outstanding	'
		1/31/14				1/31/13
	Convertible Series A Preferred Stock – Non Controlling Interest		594,930				594,930
	Convertible Series B Preferred Stock		6,686,375				6,686,375
	Convertible Series C Preferred Stock		7,010,125				7,010,125
	Convertible Series D Preferred Stock		16,031,375				17,006,375
	Convertible Loans		1,960,266,081				25,003,347
			1,990,588,886				56,301,152

Intellectual_Property_Tables

Intellectual Property (Tables) (Intellectual Property [Member])	3 Months Ended
	Jan. 31, 2014
Intellectual Property [Member]	'
Finite-Lived Intangible Assets [Line Items]	'
Summary of Periodic gross carrying amounts and related accumulated amortization	'

		1/31/14			10/31/13
	Gross Carrying Amount	$	15,256,688		$	15,256,688
	Accumulated Amortization		(6,184,371	)		(6,007,190	)
	Net Carrying Amount	$	9,072,317		$	9,249,498
Summary of Estimated amortization expense	'

	Estimated amortization expense is as follows

	10/31/2014 (Remaining)		531,542
	10/31/15		708,723
	10/31/16		708,723
	10/31/17		708,723
	10/31/18		708,723

Stockholders_Equity_and_NonCon1

Stockholders' Equity (and Non-Controlling Interest) (Tables)	3 Months Ended
	Jan. 31, 2014
Stockholders' Equity (And Non-Controlling Interest) [Abstract]	'
Summary of Non-controlling interest	'
	Non-Controlling Interest at October 31, 2010	$	570,301
	Non-Controlling Interest Converted		(25	)
	Non-Controlling interest Share of Net Loss for the Year ended October 31, 2011		(241,693	)
	Non-Controlling Interest at October 31, 2011		328,583
	Non-Controlling interest Share of Net Loss for the Year ended October 31, 2012		(219,981	)
	Non-Controlling Interest at October 31, 2012		108,602
	Non-Controlling interest Share of Net Loss for the Year ended October 31, 2013		(269,303	)
	Non-Controlling Interest at October 31, 2013		(160,701	)
	Non-Controlling interest Share of Net Loss for the three months ended January 31, 2014		(69,262	)
	Non-Controlling Interest at January 31, 2014	$	(229,963	)

Nature_of_Business_Organizatio1

Nature of Business & Organization (Details)	0 Months Ended
Nature of Business & Organization (Details)	Jan. 30, 2009
Nature of Business and Organization (Textual)	'
Share issued to the shareholders of BioNeutral Laboratories under share exchange agreement	45,000,000

Liquidity_and_Financial_Condit1

Liquidity and Financial Condition (Details) (USD $)	3 Months Ended
	Jan. 31, 2014	Jan. 31, 2013	Oct. 31, 2013	Jul. 31, 2012	Oct. 31, 2011	Dec. 12, 2012
	Jan. 31, 2014	Jan. 31, 2013	Oct. 31, 2013	Jul. 31, 2012	Oct. 31, 2011	JMJ Financial [Member]
Liquidity and Financial Condition (Textual)	'	'	'	'	'	'
Convertible promissory note	'	'	'	'	'	$250,000
Convertible promissory note amount received from related party	'	'	'	'	'	190,000
Negative working capital	2,987,203	'	'	'	'	'
Net Loss	-820,640	-761,380	'	'	'	'
Accumulated Deficit	-58,640,453	'	-57,889,075	'	'	'
Cash	1,244	'	676	70,485	3,215	'
Cash used by operations	-198,458	-308,039	'	'	'	'
Proceeds from issuance of convertible debentures	199,000	308,000	'	'	'	'
Amount of additional capital require	$2,000,000	'	'	'	'	'

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Details) (Fair Value, Measurements, Recurring [Member], USD $)	Jan. 31, 2014
Summary of Financial liabilities measured at fair value on a recurring basis	'
Derivative liability	$156,913
Quoted prices in active markets for observable identical assets (Level 1) [Member]	'
Summary of Financial liabilities measured at fair value on a recurring basis	'
Derivative liability	'
Significant other inputs (Level 2) [Member]	'
Summary of Financial liabilities measured at fair value on a recurring basis	'
Derivative liability	'
Significant unobservable inputs (Level 3) [Member]	'
Summary of Financial liabilities measured at fair value on a recurring basis	'
Derivative liability	$156,913

Summary_of_Significant_Account4

Summary of Significant Accounting Policies (Details 1) (USD $)	3 Months Ended	12 Months Ended
	Jan. 31, 2014	Oct. 31, 2013
Summary of changes in fair value of Level 3 financial liabilities measured at fair value on a recurring basis	'	'
Beginning Balance	$129,425	'
Aggregate fair value of derivative issued	36,000	337,221
Issuance date charge for difference between fair value and note proceeds	'	171,389
Change in fair value of derivative included in results of operations	-8,512	-379,185
Ending Balance	$156,913	$129,425

Summary_of_Significant_Account5

Summary of Significant Accounting Policies (Details 2)	Jan. 31, 2014	Jan. 31, 2013
Summary of common stock equivalents outstanding	'	'
Common stock equivalents outstanding	1,990,588,886	56,301,152
Convertible Preferred Stock [Member] \| Series A Preferred Stock [Member] \| Non- Controlling Interest [Member]	'	'
Summary of common stock equivalents outstanding	'	'
Common stock equivalents outstanding	594,930	594,930
Convertible Preferred Stock [Member] \| Series B Preferred Stock [Member]	'	'
Summary of common stock equivalents outstanding	'	'
Common stock equivalents outstanding	6,686,375	6,686,375
Convertible Preferred Stock [Member] \| Series C Preferred Stock [Member]	'	'
Summary of common stock equivalents outstanding	'	'
Common stock equivalents outstanding	7,010,125	7,010,125
Convertible Preferred Stock [Member] \| Series D Preferred Stock [Member]	'	'
Summary of common stock equivalents outstanding	'	'
Common stock equivalents outstanding	16,031,375	17,006,375
Convertible Loans [Member]	'	'
Summary of common stock equivalents outstanding	'	'
Common stock equivalents outstanding	1,960,266,081	25,003,347

Summary_of_Significant_Account6

Summary of Significant Accounting Policies (Details Textual)	3 Months Ended
	Jan. 31, 2014
Summary of Significant Accounting Policies (Textual)	'
Percentage of shareholders not participated in exchange of shares with acquire company	14.00%

Intellectual_Property_Details

Intellectual Property (Details) (Intellectual Property [Member], USD $)	Jan. 31, 2014	Oct. 31, 2013
Intellectual Property [Member]	'	'
Summary of Periodic gross carrying amounts and related accumulated amortization	'	'
Gross Carrying Amount	$15,256,688	$15,256,688
Accumulated Amortization	-6,184,371	-6,007,190
Net Carrying Amount	$9,072,317	$9,249,498

Intellectual_Property_Details_

Intellectual Property (Details 1) (Intellectual Property [Member], USD $)	Jan. 31, 2014
Intellectual Property [Member]	'
Summary of Estimated amortization expense	'
10/31/2014 (Remaining)	$531,542
10/31/15	708,723
10/31/16	708,723
10/31/17	708,723
10/31/18	$708,723

Intellectual_Property_Details_1

Intellectual Property (Details Textual) (Intellectual Property [Member], USD $)	3 Months Ended
	Jan. 31, 2014	Jan. 31, 2013
Intellectual Property [Member]	'	'
Intellectual Property (Textual)	'	'
Estimated useful life	'Shorter of its specific useful life, or 20 years	'
Useful life	'20 years	'
Residual value	$0	$0
Amortization expense	$177,181	$177,181

Related_Party_Payables_Details

Related Party Payables (Details) (USD $)	3 Months Ended
Related Party Payables (Details) (USD $)	Jan. 31, 2014	Jan. 31, 2013
Related Party Payables (Textual)	'	'
Interest expense on promissory notes	$518	$518

Stock_Based_Compensation_Detai

Stock Based Compensation (Details) (USD $)	0 Months Ended
Stock Based Compensation (Details) (USD $)	Dec. 11, 2013
Stock Based Compensation (Textual)	'
Cancellation of shares of stock based compensation issued to employees for compensation	1,705,152
Stock-based compensation shares issued to employees for compensation	$72,263

Stockholders_Equity_and_NonCon2

Stockholders' Equity (and Non-Controlling Interest) (Details) (USD $)	3 Months Ended		12 Months Ended
	Jan. 31, 2014	Jan. 31, 2013	Oct. 31, 2013	Oct. 31, 2012	Oct. 31, 2011
Summary of Non-controlling interest	'	'	'	'	'
Non-Controlling Interest, beginning balance	($160,701)	$108,602	$108,602	$328,583	$570,301
Non-Controlling Interest Converted	'	'	'	'	-25
Non-Controlling Interest Share of Net Loss	-69,262	-64,260	-269,303	-219,981	-241,693
Non-Controlling Interest, ending balance	($229,963)	($104,843)	($160,701)	$108,602	$328,583

Stockholders_Equity_and_NonCon3

Stockholders' Equity (and Non-Controlling Interest) (Details Textual) (USD $)

0 Months Ended

3 Months Ended

1 Months Ended

3 Months Ended

1 Months Ended

Nov. 13, 2013

Jan. 31, 2014

Dec. 11, 2013

Oct. 31, 2013

Dec. 18, 2013

Jan. 31, 2014

Oct. 31, 2013

Jan. 31, 2014

Nov. 21, 2013

Jan. 31, 2014

Dec. 19, 2013

Maximum [Member]

Minimum [Member]

Asher [Member]

JMJ Financial [Member]

BioLabs [Member]

Randy McNeil [Member]

Bemie Casamento [Member]

Bob Rutherford [Member]

GEL Properties, LLC [Member]

Restricted common stock [Member]

Series Preferred Stock [Member]

Stockholders' Equity (and Non-Controlling Interest) (Textual)

Common stock, shares authorized

4,000,000,000

3,000,000,000

4,000,000,000

1,000,000,000

Stock issued for services, shares

189,900,000

11,000,000

Price per share

$0.00

$0.01

$0.00

Marketing fees

$10,000

Non controlling interest ownership percentage

8.44%

Description of shares valued and issued

'The purchase price per share of the common stock is $.005 which was equal to the closing trading price of the Company's common stock on September 10, 2013.

'The purchase price per share of the common stock was $.0068 which is equal to the average closing trading price of the Company's common stock for the five (5) preceding days of the closing on August 16, 2013.

Shares issued upon conversion of promissory note

198,072,984

120,853,516

Aggregate amount of short term conversion of promissory note

65,450

60,632

Common stock issued under purchase agreement, shares

1,000,000

1,466,276

Common stock issued under purchase agreement

5,000

10,000

Shares issued to reduce outstanding accounts payable

24,000,000

Conversion of principal and unpaid interest

$61,474

Percentage of shareholders not participated in exchange of shares with acquire company

14.00%

Number of shares converted

59,493

Notes_Payable_Details

Notes Payable (Details) (USD $)

3 Months Ended

0 Months Ended

3 Months Ended

0 Months Ended

Jan. 31, 2014

Jan. 31, 2013

Oct. 31, 2013

Dec. 12, 2012

Jan. 31, 2013

Jan. 31, 2014

Nov. 04, 2013

Nov. 11, 2013

Jan. 14, 2014

Jan. 08, 2014

Dec. 18, 2013

Jan. 14, 2014

Jan. 08, 2014

Dec. 18, 2013

Jan. 14, 2014

Jan. 02, 2014

Jan. 14, 2014

Jan. 08, 2014

Dec. 18, 2013

Jan. 14, 2014

Nov. 05, 2013

JMJ Financial [Member]

Michael Francis [Member]

Herb Kozlov [Member]

GEL [Member]

Ben Hanafin [Member]

Ray Dunnning [Member]

Robert Machinist [Member]

Notice

Convertible Notes Payable [Member]

Convertible Notes Payable One [Member]

Convertible Notes Payable Two [Member]

Convertible Notes Payable [Member]

Convertible Notes Payable One [Member]

Convertible Notes Payable [Member]

Notice

Notes Payable (Textual)

Convertible promissory note, principal amount

$267,456

$267,716

$250,000

$81,040

$75,000

$25,444

$23,600

$25,276

$20,000

$30,000

$5,000

$25,000

Convertible promissory note, interest rate

14.00%

6.00%

18.00%

Convertible promissory note, maturity date

1-Jun-14

14-Jan-15

8-Jan-15

18-Dec-14

14-Jan-15

8-Jan-15

18-Dec-14

14-Jan-15

2-Jan-15

4-Nov-14

Description of Conversion price of notes payable

'common stock of the Company at the lower of $.03 per share, or the closing price of such shares on the day proceeding the date when the notice of full or partial conversion is tendered.

'Conversion price for each share of Common Stock equal to 65% of the lowest closing bid price of the Common Stock.

'convert the principal and interest into the Company's common stock at a conversion price equal to 50% of the average closing price of the Company's common stock for the 10 preceding days of the Maturity Date

Principal amount of note accrued and unpaid interest

18,000

23,600

Promissory note issuance date

6-Dec-10

31-Jan-13

30-Apr-13

29-Mar-13

28-Feb-13

Number of conversion notice

Shares issued as per conversion notice

189,900,000

27,500,000

51,914,879

41,438,636

Amount of common stock to settle loan proceeds

61,474

13,387

23,600

Gross proceeds from promissory note

190,000

25,000

Accrued and unpaid interest

16,667

Convertible promissory note, terms of interest rate

'JMJ Note is interest free if repaid within 90 days and if not paid within 90 days it bears interest at 10%.

Description of conversion of convertible stock

'The principal and any accrued interest are convertible into the Company's common stock at the lower of $.09 per share of 70% of the lowest trade price in the 25 days prior to conversion.

'The right to convert the principal and interest into the Company's common stock at a conversion price equal to 50% of the average closing price of the Company's common stock for the 10 preceding days of the Maturity.

Gross proceeds from issuance of convertible notes, net of discount

36,000

Amortization of debt discount

$40,424

$109,642

Commitments_Contingencies_Deta

Commitments & Contingencies (Details)	3 Months Ended	12 Months Ended
In Millions, unless otherwise specified	Jan. 31, 2014	Oct. 31, 2009
Commitments and Contingencies (Textual)	'	'
Common stock awarded under consulting contracts	'	13
Time to file appropriate statements of use with respect to trademark	'	'
	Within the six-month period from the date the USPTO issued the respective notices of allowance.	'
Number of shares issued under share exchange	6	'
Percentage of outstanding interest in BioLabs	91.00%	'
Percentage of remaining outstanding interest in BioLabs	9.00%	'

Subsequent_Events_Details

Subsequent Events (Details) (USD $)	Jun. 30, 2013	Jan. 31, 2014	Feb. 10, 2014	Feb. 10, 2014
	Convertible Promissory Note One [Member]	Subsequent Event [Member]	Subsequent Event [Member]	Subsequent Event [Member]
			Convertible Promissory Note One [Member]	Convertible Promissory Note Two [Member]
Subsequent Events (Textual)	'	'	'	'
Principal amount of note	'	'	$44,071.23	$25,000
Convertible promissory note, maturity date	'	'	10-Feb-15	10-Feb-15
Convertible promissory note, interest rate	'	'	6.00%	6.00%
Description of Conversion price of notes payable	'	'	'conversion price for each share of Common Stock equal to 65% of the lowest closing bid price of the Common Stock	'conversion price for each share of Common Stock equal to 65% of the lowest closing bid price of the Common Stock.
Accrued and unpaid interest	42,000	'	'	'
Convertible common stock shares	'	239,832,360	'	'
Convertible common stock value	'	$103,031	'	'